Updated October 7, 2021: Finland joins Sweden and Denmark in pausing the use of Moderna in men 30 years of age and younger due to heart problems after a Nordic study found that older men younger than 30 had a higher risk of developing myocarditis.
An inflammation of the heart muscle.
Updated October 6, 2021: Sweden and Denmark have discontinued the use of Moderna in people under the age of 30 due to the increased risk of heart injury such as myocarditis. Slovenia temporarily stopped Johnson & Johnson.
Updated September 9, 2021: Pfizer’s Covid-19 mRNA vaccine was associated with a threefold increase in myocarditis risk, according to a real-world case-control study from Israel.
“Vaccination had a strong association with an increased risk of myocarditis and an increased risk of lymphadenopathy [swelling or inflammation of the lymph nodes], appendicitis and herpes zoster infection.”
The Food and Drug Administration has added a new warning to Pfizer and Moderna’s Covid-19 vaccines about the risk of heart inflammation.As of June 2021, the CDC said more than 1,200 cases of cardiac inflammation (myocarditis or pericarditis) in young people had been reported after Pfizer and Moderna Covid-19 vaccinations.
More than half were after the second dose.
Most of the lesions are in males under the age of 30.Updated August 4: A new independent medical record study found that the incidence of myocarditis and pericarditis is more than five times more common than the CDC reported.
The Israeli Ministry of Health has announced that it is monitoring heart inflammation after Pfizer’s vaccine due to reports of problems.Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines [Pfizer-BioNTech, Moderna] in a number of patients are described in a scientific article:
- Two patients with clinically suspected myocarditis
- A patient with stress cardiomyopathy
- Two patients with pericarditis
According to the research:
The two patients with clinically suspected myocarditis were otherwise healthy young men who presented with acute substernal chest pressure and / or dyspnoea after receiving the second dose of the vaccine and were found to have widespread elevations in ST on electrocardiogram (ECG), elevated cardiac biomarkers and inflammatory markers and slightly reduced left ventricular (LV) function on echocardiography.
Both patients met the modified Lake Louise criteria for acute myocarditis using cardiac magnetic resonance imaging.One case of stress cardiomyopathy occurred in a 60-year-old woman with known coronary artery disease (CAD) and previously normal LV function, who presented with new exertion symptoms, ECG changes, and apical akinesis after the second dose of the vaccine.
Reactivation and death from hepatitis C
- The two patients with pericarditis who presented with chest pain, elevated inflammatory markers, and pericardial effusions after receiving the vaccine.
- Updated September 9, 2021: An August 10 study in JAMA Cardiology confirms the previously identified Pfizer vaccine risk of myocarditis (heart inflammation) in young boys.
Updated September 12, 2021: A Pfizer and Moderna vaccine study finds teenage boys are six times more likely to suffer from heart problems from Covid-19 vaccination than from Covid. (However, in both cases, the risk is considered small.)
Update 3 October 2021: Scientists in the Netherlands report that an elderly woman suffered from “reactivation of hepatitis C infection after vaccination with the Pfizer-BioNTech COVID-19 mRNA-based vaccine.
This reactivation has manifested itself with jaundice, loss of consciousness, hepatic coma and death ”suggesting“ the need for critical consideration of individuals with prior HCV infection and considered for COVID-19 vaccination ”.